GSK plc
GLAXF · OTC
10/28/2025 | 9/30/2025 | 6/30/2025 | 3/31/2025 | |
|---|---|---|---|---|
| Revenue | $9 | – | $8 | $8 |
| % Growth | – | – | 6.3% | – |
| Cost of Goods Sold | $2 | – | $2 | $2 |
| Gross Profit | $6 | – | $6 | $6 |
| % Margin | 73.6% | – | 72.9% | 74.2% |
| R&D Expenses | $2 | – | $2 | $1 |
| G&A Expenses | $2 | – | $2 | $2 |
| SG&A Expenses | $2 | – | $2 | $2 |
| Sales & Mktg Exp. | $0 | – | $0 | $0 |
| Other Operating Expenses | -$0 | – | -$0 | -$0 |
| Operating Expenses | $4 | – | $4 | $3 |
| Operating Income | $3 | – | $2 | $2 |
| % Margin | 30.3% | – | 25.3% | 29.5% |
| Other Income/Exp. Net | -$0 | – | -$0 | -$0 |
| Pre-Tax Income | $2 | – | $2 | $2 |
| Tax Expense | $0 | – | $0 | $0 |
| Net Income | $2 | – | $1 | $2 |
| % Margin | 23.6% | – | 18.1% | 21.6% |
| EPS | 2.86 | – | 0.36 | 0.4 |
| % Growth | – | – | -10% | – |
| EPS Diluted | 2.82 | – | 0.35 | 0.39 |
| Weighted Avg Shares Out | 4 | – | 4 | 4 |
| Weighted Avg Shares Out Dil | 4 | – | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | – | $0 | $0 |
| Interest Expense | $0 | – | $0 | $0 |
| Depreciation & Amortization | $1 | – | $1 | $1 |
| EBITDA | $3 | – | $3 | $3 |
| % Margin | 39.3% | – | 40.4% | 41.2% |